NCT07066566 The Effect of Asymmetrical vs. Symmetrical High Flow Nasal Cannula on the Work of Breathing
| NCT ID | NCT07066566 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Larissa University Hospital |
| Condition | Respiratory Disease (Clinically Stable Individuals - Patients Recovered From Respiratory Disease) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-04-09 |
| Primary Completion | 2025-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-04-09 with a primary completion date of 2025-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study randomized single-center crossover study is to evaluate the impact of asymmetrical versus symmetrical nasal high flow (NHF) therapy on work of breathing (WOB). The main question it aims to answer are: 1\. Does the asymmetrical NHF interface improve the work of breathing compared to the symmetrical NHF interface? Researchers will compare the symmetrical NHF interface to the symmetrical NHF interface to see if the the asymmetrical interface has a greater impact on the work of breathing. Participants will : 1. receive NHF via both interfaces (FiO₂ 0.21, 50 L/min) for 15 minutes, in random order, with esophageal pressure monitoring and bioelectrical impedance analysis performed. 2. baseline characteristics will me monitored throughout the interventions 3. Esophageal pressure and minute ventilation will be monitored.
Eligibility Criteria
Inclusion Criteria: 1. age ≥18 years old 2. absence of symptoms and signs of respiratory failure (SpO2\>95% at FiΟ2 0.21) Exclusion Criteria: 1. pregnancy 2. SpO2\<94% at FiΟ2 0.21 3. neuromuscular disease 4. contraindications to esophageal pressure monitoring (e.g., uncontrolled coagulopathy, esophageal disease, nasal trauma, allergy to local lidocaine)
Contact & Investigator
Demosthenes Makris
STUDY CHAIR
Professor of Intensive Care Unit, University Hospital of Larissa
Frequently Asked Questions
Who can join the NCT07066566 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Respiratory Disease (Clinically Stable Individuals - Patients Recovered From Respiratory Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07066566 currently recruiting?
Yes, NCT07066566 is actively recruiting participants. Contact the research team at pantazopoulosioannis@yahoo.com for enrollment information.
Where is the NCT07066566 trial being conducted?
This trial is being conducted at Larissa, Greece.
Who is sponsoring the NCT07066566 clinical trial?
NCT07066566 is sponsored by Larissa University Hospital. The principal investigator is Demosthenes Makris at Professor of Intensive Care Unit, University Hospital of Larissa. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.